Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | General Counsel | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,959 |
Ending reported balance
After 2026-03-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-17 · Sale · Disposed 4,084 · Balance 72,315 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 2 · 2026-03-18 · Sale · Disposed 4,125 · Balance 68,190 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 3 · 2026-03-19 · Sale · Disposed 4,231 · Balance 63,959 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,231 | $67.00 | $283,477.00 |
DisclosureSEC source: 0001841401-26-000007 · wk-form4_1773961481.xml · nonDerivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,959 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,125 | $68.71 | $283,428.75 |
DisclosureSEC source: 0001841401-26-000007 · wk-form4_1773961481.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,190 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,084 | $69.42 | $283,511.28 |
DisclosureSEC source: 0001841401-26-000007 · wk-form4_1773961481.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,315 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 5 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,067 Underlying: Common Stock · 5,022 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 7,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 4 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,351 Underlying: Common Stock · 7,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 7,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,249 Underlying: Common Stock · 7,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 24,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 451 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 17,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-26-000003 · wk-form4_1773086812.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,161 Underlying: Common Stock · 17,161 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 27,310 | $0.00 Strike: $74.90 | $0.00 |
DisclosureSEC source: 0001841401-26-000003 · wk-form4_1773086812.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,310 Underlying: Common Stock · 27,310 shares Expires 2026-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,084 | $50.11 | $154,539.24 |
DisclosureSEC source: 0001819790-25-000057 · wk-form4_1742521746.xml · nonDerivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,712 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,261 | $47.40 | $154,571.40 |
DisclosureSEC source: 0001819790-25-000057 · wk-form4_1742521746.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,796 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,341 | $46.29 | $154,654.89 |
DisclosureSEC source: 0001819790-25-000057 · wk-form4_1742521746.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,057 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 7,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · derivative · entry 4 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,527 Underlying: Common Stock · 7,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 7,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,497 Underlying: Common Stock · 7,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,790 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 19,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 20,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000023 · wk-form4_1741382286.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,089 Underlying: Common Stock · 20,089 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 30,628 | $0.00 Strike: $44.54 | $0.00 |
DisclosureSEC source: 0001819790-25-000023 · wk-form4_1741382286.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,628 Underlying: Common Stock · 30,628 shares Expires 2035-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,436 | $30.60 | $135,741.60 |
DisclosureSEC source: 0001819790-24-000046 · wk-form4_1710889541.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,951 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 7,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000046 · wk-form4_1710889541.xml · derivative · entry 4 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,745 Underlying: Common Stock · 7,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000046 · wk-form4_1710889541.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,580 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 12,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000046 · wk-form4_1710889541.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 1,383 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:45 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 28,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-24-000001 · wk-form4_1710193510.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,702 Underlying: Common Stock · 28,702 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:45 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001841401-24-000001 · wk-form4_1710193510.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,356 | $16.31 | $136,286.36 |
DisclosureSEC source: 0001841401-23-000007 · wk-form4_1701467742.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,966 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 23,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-23-000007 · wk-form4_1701467742.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F3 · derivative.exercise_date: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 23,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-23-000007 · wk-form4_1701467742.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2023. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:52 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 371 | $12.15 | $4,507.65 |
DisclosureSEC source: 0001841401-23-000004 · wf-form4_167961555155059.xml · nonDerivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,402 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:52 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 357 | $12.64 | $4,512.48 |
DisclosureSEC source: 0001841401-23-000004 · wf-form4_167961555155059.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,773 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:52 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 350 | $12.89 | $4,511.50 |
DisclosureSEC source: 0001841401-23-000004 · wf-form4_167961555155059.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,130 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 23:14 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 357 | $12.61 | $4,501.77 |
DisclosureSEC source: 0001841401-23-000002 · wf-form4_167944048401877.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,480 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:14 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 339 | $13.28 | $4,501.92 |
DisclosureSEC source: 0001841401-23-000002 · wf-form4_167944048401877.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,837 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 337 | $13.43 | $4,525.91 |
DisclosureSEC source: 0001209191-23-019884 · doc4.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,176 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019884 · doc4.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,370 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 4,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-019884 · doc4.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:29 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 28,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018004 · doc4.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,993 Underlying: Common Stock · 28,993 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:29 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 42,802 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018004 · doc4.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,802 Underlying: Common Stock · 42,802 shares Expires 2033-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,154 | $16.90 | $19,502.60 |
DisclosureSEC source: 0001841401-22-000006 · wf-form4_167036696162484.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,723 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 00:58 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,164 | $16.75 | $19,497.00 |
DisclosureSEC source: 0001841401-22-000004 · wf-form4_166994271203193.xml · nonDerivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,877 F3 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 00:58 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,183 | $16.50 | $19,519.50 |
DisclosureSEC source: 0001841401-22-000004 · wf-form4_166994271203193.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,041 F3 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 00:58 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 10,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-22-000004 · wf-form4_166994271203193.xml · derivative · entry 4 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,920 Underlying: Common Stock · 10,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F4 · derivative.exercise_date: RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 00:58 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 10,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-22-000004 · wf-form4_166994271203193.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2022. F2 · balance_after: Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:15 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 34,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-22-000002 · wf-form4_164703330355786.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,171 Underlying: Common Stock · 34,171 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: 30% of the RSUs will vest on November 29, 2022 and 70% of the RSUs will vest on November 29, 2023 subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: 30% of the RSUs will vest on November 29, 2022 and 70% of the RSUs will vest on November 29, 2023 subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:15 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 19,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-22-000002 · wf-form4_164703330355786.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 Underlying: Common Stock · 19,160 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:15 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 65,312 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0001841401-22-000002 · wf-form4_164703330355786.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,312 Underlying: Common Stock · 65,312 shares Expires 2032-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 00:57 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 89,368 | $0.00 Strike: $37.44 | $0.00 |
DisclosureSEC source: 0001209191-21-006987 · doc4.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,368 Underlying: Common Stock · 89,368 shares Expires 2031-02-02 F1 · derivative.exercise_date: Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on January 19, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.